From BioProcess International
Ciloa says its exosomes can ‘deliver’ large molecules and viral proteins to specific organs and is setting up a clinical plant in Montpellier, France.
The €1 million ($1.2 million) investment will be used to create an exosome production unit at Ciloa’s site in Montpellier. The facility will be a technological demonstrator that will be the prototype for larger projects of production of customized exosomes, capable of producing around 1,000 doses to support early clinical trials…